ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 700

Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial

Guro Løvik Goll1, Nils Bolstad2, Ines Iria3,4, Rolf Klaasen5, Kristin Kaasen Jørgensen6, Inge C Olsen7, Ana Valido8, Maria J Saavedra9, João E. Fonseca10, Merete Lorentzen11, Cato Mork12, Knut EA Lundin13, David J Warren14, Espen A. Haavardsholm15, Jorgen Jahnsen16, Tore Kvien15 and João Gonçalves17, 1Department of Rheumathology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway, 3Dept Pharmacology, Faculdade de Farmacia da Universidade de Lisboa, Lisbon, Portugal, 4iMed- Research Institute for medicines, Lisbon, Portugal, 5Dartment of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, 6Dept Gastroenterology, Akershus University Hospital, Lørenskog, Norway, 7Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 8Rheumatology, Centro Hospitalar Lisboa Norte, Lisbon, Portugal, 9Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria, CHLN, Lisbon, Portugal, 10Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 11Dept of Dermatology, Rikshospitalet, Oslo, Norway, 12Dept of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway, 13Dept of gastroenterology, Oslo University Hospital, Oslo, Norway, 14Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, 15Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 16Dept of Gastroenterology, Akershus University Hospital, Lørenskog, Norway, 17Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: , ,

Session Information

Date: Sunday, October 21, 2018

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

The NOR-SWITCH study was funded by the Norwegian government to investigate switching from originator infliximab (INX) to biosimilar CT-P13, in spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (Ps), Crohn’s disease (CD) and ulcerative colitis (UC). Previously, the primary analyses of the pooled indications have been published1. Anti-drug antibodies (ADAb) are associated with treatment failure and have been a concern in switching. Here, we investigate immunogenicity of infliximab in patients treated with originator INX vs patients switched to CT-P13; between patients with different inflammatory diseases; and the epitope specificities of ADAb.

Methods:

The study was a 52-week randomized, double-blind, non-inferiority, phase IV trial and included adult patients with SpA, RA, PsA, UC, CD or Ps on originator INX. Patients were randomized 1:1 to either continued INX or switch to CT-P13 treatment. Assays for drug serum levels and neutralizing ADAb are fully automated on the AutoDELFIA® (PerkinElmer, Waltham, MA) immunoassay platform. Immunogenic infliximab-epitopes were identified by ELISA and comparison of sera from patients with CD, UC, SpA, RA, PsA or Ps was performed.

Results:

20 patients entered the study with detectable ADAb (9 in INX arm, 11 in CT-P13 arm). 36 patients (17 in INX-arm, 19 in CT-P13 arm) developed incident ADAb during the 52-week main study period with no consistent difference between diseases though numbers are small. 36 patients’ and 15 control sera were tested for epitope specificity. No Ps patients developed ADAbs in our study. All anti-CT-P13 and anti-INX sera were cross-reactive with INX and CT-P13, respectively. ADAb concentrations against INX or CT-P13 were strongly correlated (r values 0.92 – 0.99, p<0.001 for all experiments, Spearman’s correlation test). ADAb-negative controls (10 healthy individuals, 5 patients with RA) were negative for both INX and CT-P13. Recognition of 5 different batches of CT-P13 and INX by IgG4 ADAb were similar between all tested sera. ADAb in 60%-79% of patients recognized 7 synthetic peptides, with no significant differences between CT-P13 and INX ADAb. However, two epitopes were specifically recognized in UC and CD but not in rheumatic patients. Patients with detectable ADAb at any time were more likely to discontinue study drug treatment (7/26 (26.9 %) in INX arm, 5/30 (16.7 %) in CT-P13 arm) than patients without detectable ADAb (17/214 (7.9 %) in INX arm, 13/210 (6.2 %) in CT-P13 arm) (p=0.001).

Studies on a possible association between HLA and ADAb responses are ongoing.

Conclusion:

ADAb occured to a similar degree in the two study arms and ADAb to originator INX also recoginized CT-P13. The majority of patients show no consistent difference in epitope specificity between RA, SpA, PsA, UC and CD patients. However, two specific minor epitopes are only recognized by IBD patients which might reflect the importance of HLA background for ADAb response.

1Jørgensen KK, Olsen IC, Goll GL et al. Switching from originator infliximab to biosimilar CT-P13 compared to maintained treatment with originator infliximab (NOR-SWITCH): a 52-week randomised double-blind non-inferiority trial. The Lancet, 2017; 389:2304-16.

Disclosure: G. L. Goll, AbbVie, Boeringer Ingelheim, Eli Lilly, Novartis, Pfizer, Orion Pharma, Roche, Sandoz, 5; N. Bolstad, Roche, 5,Orion Pharma, 5,Napp Pharma, 5,Pfizer, Inc., 5,Takeda, 5,Janssen, 5; I. Iria, None; R. Klaasen, None; K. K. Jørgensen, Tillots, Celltrion, Intercept, Sandoz, 5; I. C. Olsen, Pfizer, Inc., 5; A. Valido, None; M. J. Saavedra, None; J. E. Fonseca, AbbVie Inc., 2, 8,Pfizer, Inc., 2, 8,Merck & Co., 2, 8,Bayer, 2, 8,Janssen, 2, 8,Roche, 2, 8,UCB, Inc., 2,Novartis, 2, 8; M. Lorentzen, None; C. Mork, Novartis, 5,LEO Pharma, 5,ACO hud, 5,AbbVie Inc., 5,Galderma Nordic, 5,Cellgene, 5; K. E. Lundin, AbbVie Inc., 5,MSD, 5,Takeda, 5,Orion Pharma, 5,Hospira, 5,Tillots, 5,Bioniz, 5,Immusan T, 5; D. J. Warren, None; E. A. Haavardsholm, Pfizer, Eli Lilly, Janssen-Cilag, Roche, Celegene, Pfizer, UCB, Roche, AbbVie, MSD, EliLilly, 5,Pfizer, UCB, Roche, MSD, AbbVie, 2; J. Jahnsen, Orion Pharma, 5,Celltrion, 5,Janssen, 5,Pfizer, Inc., 5,MSD, 5,AbbVie Inc., 5,Takeda, 5,Napp Pharma, 5,Roche, 5,Boeringer Ingelheim, 5,Astro Pharma, 5,Mundi Pharma, 5,Sandoz, 5; T. Kvien, AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Epirus, Hospira, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB, 5, 8,AbbVie, BMS, MSD, Pfizer, Roche, UCB., 2; J. Gonçalves, AbbVie Inc., 5,Amgen Inc., 5,Biogen, 5,MSD, 5,Pfizer, Inc., 5.

To cite this abstract in AMA style:

Goll GL, Bolstad N, Iria I, Klaasen R, Jørgensen KK, Olsen IC, Valido A, Saavedra MJ, Fonseca JE, Lorentzen M, Mork C, Lundin KE, Warren DJ, Haavardsholm EA, Jahnsen J, Kvien T, Gonçalves J. Immunogenicity of Originator and Biosimilar Infliximab: Anti-Drug Antibody Occurence, Cross-Reactivity and Epitope Specificities across Six Diseases. Analyses from a Norwegian Randomized Switching Trial [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/immunogenicity-of-originator-and-biosimilar-infliximab-anti-drug-antibody-occurence-cross-reactivity-and-epitope-specificities-across-six-diseases-analyses-from-a-norwegian-randomized-switching-tri/. Accessed December 9, 2019.

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunogenicity-of-originator-and-biosimilar-infliximab-anti-drug-antibody-occurence-cross-reactivity-and-epitope-specificities-across-six-diseases-analyses-from-a-norwegian-randomized-switching-tri/